Massachusetts-based Biotechnology company Curis has announced a registered direct offering of 18.4 million common shares. The company aims to raise approximately USD 15.1 million for USD 0.82 per share. The offering is expected to close on July 10, 2023.
The net proceeds are expected to be utilized in R&D, working capital, and general corporate purposes.
Curis is a biotechnology company focused on the development of innovative cancer therapeutics. Its lead product, Erivedge, is approved for treating advanced basal cell carcinoma. Curis has multiple drug candidates in development, including Fimepinostat, CA-170, CA-4948, and CI-8993, targeting various cancer types. Through collaborations with Aurigene, ImmuNext, and Genentech, Curis is working on various treatments, including immune checkpoint antagonists and kinase inhibitors, which are currently undergoing clinical testing for hematologic malignancies and other cancer types.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.